CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections

Debiopharm to Showcase Research Results of Their First-In-Class Anti-Staphylococcal Program at IDWeek 2024 in Los Angeles

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-Based Radiopharmaceutical Programs Targeting Solid Tumors

The First-in-Class Anti-Staphylococcal Antibiotic Afabicin Desphosphono is Not Associated With Clostridioides difficile Infection in an in vitro Human Gut Model

Assessment of Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment for the Anti-Staphylococcal Antibiotic Afabicin

Results from A Phase 2 Clinical Trial for Treatment of Bone And Joint Infections with Afabicin, A First-in-Class Selective Anti-Staphylococcal…